Products
Cugrastomig Biosimilar Bispecific Antibody (LAG-3 × PD-1) for Research
Cat No.: GMP-Bios-INN-1147
Anti-LAG3/CD223 therapeutic antibody (Pre-made Cugrastomig biosimilar,Bispecific Mixed mAb and scFv) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Cugrastomig (development code AK 129) is a bispecific antibody targeting LAG3 and PD-1 (PDCD1). It is developed by Akeso Biopharma and Kangfang Huike (Shanghai) Biology Co for HER2-negative gastric cancer, neoplasms, refractory Hodgkin lymphoma. It is in Phase I/II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1147-1mg | 1mg | |
| GMP-Bios-INN-1147-10mg | 10mg | |
| GMP-Bios-INN-1147-100mg | 100mg | |
| GMP-Bios-INN-1147-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Cugrastomig biosimilar, Bispecific Mixed mAb and scFv, Anti-LAG3/CD223;PDCD1/CD279/PD1 Antibody: Anti-CD223/PD-1/CD279/PDCD1 therapeutic antibody |
| INN Name | Cugrastomig |
| Target | LAG3/CD223;PDCD1/CD279/PD1 |
| Format | Bispecific Mixed mAb and scFv |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1;na |
| VD LC | Kappa;Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | 7um3:HL:IM;None |
| Year Proposed | 2024 |
| Year Recommended | 2024 |
| Companies | Akeso Biopharma;Kangfang Huike (Shanghai) Biology Co |
| Conditions Approved | na |
| Conditions Active | HER2-negative gastric cancer;Neoplasms;Refractory Hodgkin Lymphoma |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
